This study aimed to evaluate if macular autofluorescence(MAF) is a valuable, non-invasive follow-up parameter for cystoid macular edema. A total of 71 eyes(71 cases) with cystoid macular edema(CME) were included in th...This study aimed to evaluate if macular autofluorescence(MAF) is a valuable, non-invasive follow-up parameter for cystoid macular edema. A total of 71 eyes(71 cases) with cystoid macular edema(CME) were included in the study. Macular pigment(MP) was evaluated using HRA2(infrared) IF and FA models. The density of MP was graded into three categories: without, partial, and normal amount of MP. A comparison was made between the baseline(before the first administration) level and at the fourth month, following three consecutive intravitreal lucentis injections every month. The morphology and distribution of MAF, and the density and distribution of MP were regarded as the main outcome measures. At the baseline visit, all eyes with CME had petaloid/irregular-shaped MAF in the macular area(100%). No MAF was detected in the control eyes(0). There was significant difference in MAF between the CME and normal groups(P=0.000). At the fourth monthly visit, normal levels of MP density without MAF was detected in 68 eyes(95.8%) with the best corrected spectacular visual acuity increasing to at least 1 line accordingly. We conclude that macular MAF can be used as a follow-up parameter for patients with CME. MP and MAF can indirectly reflect the fovea cone function.展开更多
基金partly supported by the National Natural Science Foundation of China(81170859)Beijing Municipal Education Commission Key Project(KZ201210025027)Beijing Science and Technology New Star Project(2004B28)
文摘This study aimed to evaluate if macular autofluorescence(MAF) is a valuable, non-invasive follow-up parameter for cystoid macular edema. A total of 71 eyes(71 cases) with cystoid macular edema(CME) were included in the study. Macular pigment(MP) was evaluated using HRA2(infrared) IF and FA models. The density of MP was graded into three categories: without, partial, and normal amount of MP. A comparison was made between the baseline(before the first administration) level and at the fourth month, following three consecutive intravitreal lucentis injections every month. The morphology and distribution of MAF, and the density and distribution of MP were regarded as the main outcome measures. At the baseline visit, all eyes with CME had petaloid/irregular-shaped MAF in the macular area(100%). No MAF was detected in the control eyes(0). There was significant difference in MAF between the CME and normal groups(P=0.000). At the fourth monthly visit, normal levels of MP density without MAF was detected in 68 eyes(95.8%) with the best corrected spectacular visual acuity increasing to at least 1 line accordingly. We conclude that macular MAF can be used as a follow-up parameter for patients with CME. MP and MAF can indirectly reflect the fovea cone function.
